Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels
Omalizumab (anti-IgE) therapy in the asthma-COPD overlap syndrome (ACOS) and its effects on circulating cytokine levels
复制标题
DOI：
10.3109/08923973.2016.1173057
复制
发表时间：
2016-06-01
影响因子：
3.3
通讯作者：
Yalcin, Ata Nevzat
中科院分区：
文献类型：
--
作者：
Yalcin, Arzu Didem;Celik, Betul;Yalcin, Ata Nevzat
内容：哮喘-慢性阻塞性肺疾病（COPD）重叠综合征（ACOS）一词已被应用于条件，其中一个人有哮喘和COPD的临床特征。方法：患者（N=10）到我们的诊所与低肺功能，有限的可逆性气道阻塞，过度充气，异常的身体成分，呼吸困难和阵发性喘息。根据临床和实验室检查结果，患者被诊断为ACOS。检测患者血清IL-2、sIL-4、sIL-6、sIL-10、sIL-17、sTNF-α和sIFN-α水平作为凋亡标志物和炎症标志物。接受奥马珠单抗治疗和长期（12个月）后，患者的IgE、呼出气一氧化氮浓度分数（FENO）、嗜酸性粒细胞、中性粒细胞、巨噬细胞，结论：据我们所知，这是首次证实奥马珠单抗用于ACOS。我们证实了IL-4降低，过敏性肺部症状（呼吸困难，喘息，支气管高反应性）和偏头痛发作的患者。
Context: The term asthma-chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) has been applied to the condition, in which a person has clinical features of both asthma and COPD.Methods: The patients (N=10) were presented to our clinic with low lung function, limited reversibility of airway obstruction, hyperinflation, abnormal body composition, dyspnea and episodic wheezing. Based on the clinical and laboratory findings, the patients were diagnosed with ACOS. Patients' serum IL-2 (sIL-2), sIL-4 sIL-6, sIL-10, sIL-17, sTNF- and sIFN- levels were investigated as an apoptotic marker and a marker for inflammation.Results: Having undergone omalizumab treatment and a long-term (12 months) later, patients had a decreased IgE, fractional exhaled nitric oxide concentrations (FENO), eosinophil, neutrophils, macrophages, eosinophil cationic peptide (ECP) and sIL-4 levels.Conclusion: To our knowledge, this is the first documentation of omalizumab use in ACOS. We demonstrated decreased IL-4, allergic pulmonary symptoms (dyspnea, wheezing, bronchial hyper responsiveness) and migraine attacks in the patients.